| Related Articles |
A new class of drugs for systolic heart failure: The PARADIGM-HF study.
Cleve Clin J Med. 2015 Oct;82(10):693-701
Authors: Sabe MA, Jacob MS, Taylor DO
Abstract
The PARADIGM-HF trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) found a combination drug containing sacubitril (a neprilysin inhibitor) and valsartan (an angiotensin II receptor blocker) superior to enalapril (an angiotensin-converting enzyme inhibitor) in patients with systolic heart failure. Recently approved by the US Food and Drug Administration, sacubitril-valsartan is the first new drug in over a decade to decrease death rates in patients with systolic heart failure.
PMID: 26469827 [PubMed - as supplied by publisher]